We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -16.33% | 10.25 | 10.00 | 10.50 | 12.25 | 10.25 | 12.25 | 277,553 | 16:22:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.20 | 39.87M |
TIDMREDX
Redx Pharma plc
13 November 2017
Hardman Research: Streamlined and clean
Streamlined and clean - Redx has emerged from administration with a refocused R&D pipeline and in a very clean financial state with GBP13.6m net cash in the bank. The group's strategy has been validated by the successful disposal of its pre-clinical programme BTK for $40m. The new Board & Management team will focus resources on the early clinical development of its next two lead candidates, in oncology and fibrotic disease, which are expected to start Phase I trials in 2018 and 2019, respectively. There was an inevitable knee-jerk reaction when the shares were re-quoted but consideration should be given to the potential value within the focused pipeline.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/13.11.17-streamlined-and-clean.pdf
To contact us: Contacts: mh@hardmanandco.com Hardman & Co Dr Martin dmh@hardmanandco.com 35 New Broad Street Hall gp@hardmanandco.com London Dr Dorothea hardman@hardmanandco.com EC2M 1NH Hill Follow us on Twitter Dr Gregoire @HardmanandCo Pave +44 20 7194 7622
About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVRLRLILID
(END) Dow Jones Newswires
November 13, 2017 02:15 ET (07:15 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions